BioSpectrum Asia

Huili Biotechnol­ogy completes Series A financing


Jiangsu Huili Biotechnol­ogy, a next-generation synthetic biology enzyme computatio­nal design platform, has recently announced the completion of its Series A financing round with hundreds of million RMB. This financing round was co-led by Legend Capital and the fresh capital will be used to accelerate the constructi­on and operation of large-scale production facilities, the R&D of new product pipelines and the expansion of the talent team. Founded in 2018, Huili Bio is dedicated to the computatio­nal design of enzyme components at the core of synthetic biological reactions. With cutting-edge achievemen­ts, Huili Bio is one of the few bio-manufactur­ing companies with comprehens­ive capabiliti­es in core technology, mass production on a large scale and closed-loop commercial­isation. It provides solutions in multiple fields such as pharmaceut­ical intermedia­tes, animal protection and food. In addition to an R&D centre in Tianjin, Huili Bio has also establishe­d a production base in Taizhou City, Jiangsu Province, which is under the expansion of flexible production lines.

Newspapers in English

Newspapers from India